Ripretinib [RIP1]

Ripretinib for treating advanced gastrointestinal stromal tumours after 3 more kinase inhibitors where the following criteria have been met:

1. This application is being made by and the first cycle of systemic anti-cancer therapy will be prescribed by a consultant, or internally accredited oncology specialty trainee, specifically trained and assessed in the use of systemic anti- cancer therapy.
2. The patient has histologically confirmed metastatic or unresectable gastrointestinal stromal tumour (GIST).
3. The patient has a performance status of 0-2.
4. The patient has had disease progression on, or intolerance to, previous imatinib.
5. The patient has had disease progression on, or intolerance to, previous sunitinib. or
6. The patient has had disease progression on, or intolerance to, previous regorafenib
7. Ripretinib will be dosed at 150mg once daily ONLY in line with the Marketing Authorisation
8. Ripretinib is to be continued until loss of clinical benefit or unacceptable toxicity or patient choice to stop treatment, whichever is the sooner.
9. Where a treatment break of more than 6 weeks beyond the expected cycle length is needed for toxicity, a treatment break approval form will be completed to restart treatment, which MUST be approved before treatment with ripretinib is recommenced.
10. Ripretinib is to be otherwise used as set out in its Summary of Product Characteristics (SPCs).

NHS funded From: 27 July 2026

Additional information

Form version: -

CDF Managed Access: NA

NICE Technology Appraisal: TA1146 (28 April 2026)

Current Form Version

Note

The data on this page was produced using version 1.406 of the CDF list, downloaded from NHS England’s website on 09 September 2026 at 21:36.

If NHS England has published a new version of the CDF List but this site has not yet accessed that, this form may be out of date. Additionally, if any update has occurred without NHS England noting it as a change, this page will be out of date.

Older Form Versions

There are previous versions of this form. These may not all be available on this site.

• RIP1_prior_to_cdf_1.406